Patient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovir

AIDS Patient Care and STDs

Volumn 26, Issue 6, 2012, Pages 312-319

  Edelman, E Jennifer ^a,b   Gordon, Kirsha ^b   Rodriguez Barradas, Maria C ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; EFAVIRENZ; EMTRICITABINE; RITONAVIR; TENOFOVIR;

ADULT; ANOREXIA; ANXIETY; ANXIETY DISORDER; ARTICLE; BLOATING; CHILL; COMORBIDITY; COMPARATIVE STUDY; COUGHING; CROSS-SECTIONAL STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DYSPNEA; FATIGUE; FEMALE; FEVER; HAIR LOSS; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MYALGIA; NAUSEA AND VOMITING; NERVOUSNESS; OUTCOME ASSESSMENT; PARESTHESIA; PATIENT COMPLIANCE; PRURITUS; QUALITY OF LIFE; RASH; SELF REPORT; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN TINGLING; SLEEP DISORDER; STOMACH PAIN; SYMPTOM; VETERAN; WEIGHT REDUCTION;

ADENINE; ANTI-HIV AGENTS; BENZOXAZINES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VETERANS;

EID: 84862190292     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2012.0044     Document Type: Article

References (57)

1. Duran S, Spire B, Raffi F, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials 2001;2:38-45. (Pubitemid 32181748)
2. Johnson MO, Charlebois E, Morin SF, et al. Perceived adverse effects of antiretroviral therapy. J Pain Symptom Manage 2005;29:193-205. (Pubitemid 40279056)
3. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001;28:445-449. (Pubitemid 34033195)
4. Lorenz KA, Cunningham WE, Spritzer KL, Hays RD. Changes in symptoms and health-related quality of life in a nationally representative sample of adults in treatment for HIV. Qual Life Res 2006;15:951-958. (Pubitemid 44221449)
5. Mrus JM, Leonard AC, Yi MS, et al. Health-related quality of life in veterans and nonveterans with HIV/AIDS. J Gen Intern Med 2006;21(Suppl 5):S39-47. (Pubitemid 44657036)
6. Burgoyne RW, Rourke SB, Behrens DM, Salit IE. Long-term quality-of-life outcomes among adults living with HIV in the HAART era: The interplay of changes in clinical factors and symptom profile. AIDS Behav 2004;8:151-163. (Pubitemid 38888109)
7. Mannheimer SB, Wold N, Gardner EM, et al. Mild-tomoderate symptoms during the first year of antiretroviral therapy worsen quality of life in HIV-infected individuals. Clin Infect Dis 2008;46:941-945. (Pubitemid 351417202)
8. Carrieri P, Spire B, Duran S, et al. Health-related quality of life after 1 year of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003;32:38-47. (Pubitemid 36091483)
9. Burgoyne R, Collins E, Wagner C, et al. The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults. Qual Life Res 2005;14:981-990. (Pubitemid 40685222)
10. Edelman EJ, Gordon K, Justice AC. Patient and providerreported symptoms in the post-cART era. AIDS Behav 2011;15:853-861.
11. Cleary P, Fowler FJ Jr, Weissman J, Massagli MP, Wilson I, Seage GR 3rd, Gatsonis C, Epstein A. Health-related quality of life in persons with acquired immune deficiency syndrome. Med Care 1993;31:569-580.
12. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-260. (Pubitemid 43113030)
13. Dejesus E, Young B, Morales-Ramirez JO, et al. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr 2009;51:163-174.
14. Rockstroh JK, Lennox JL, Dejesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/ emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011;53:807-816.
15. Hodder SL, Mounzer K, Dejesus E, et al. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care STDS 2010;24:87-96.
16. Molina JM, Journot V, Morand-Joubert L, et al. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial. J Infect Dis 2005;191:830-839. (Pubitemid 40349796)
17. DeJesus E, Ruane P, McDonald C, et al. Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine. HIV Clin Trials 2008;9:103-114. (Pubitemid 351804394)
18. Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011;204:1191-1201.
19. Tan DH, Chan K, Raboud J, et al. Comparison of abacavir/ lamivudine and tenofovir/emtricitabine among treatmentnaive HIV-infected patients initiating therapy. J Acquir Immune Defic Syndr 2011;58:38-46.
20. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents In HIV-1 Infected Adults And Adolescents. Washington, DC: Department of Health and Human Services; 2011.
21. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321-333.
22. European AIDS Clinical Society. Guidelines Clinical Management and Treatment of HIV-Infected Adults in Europe. 2011; version 6: http://www.europeanaidsclinicalsociety.org/ guidelines.asp.Paris.
23. McKinnell JA, Willig JH, Westfall AO, et al. Antiretroviral prescribing patterns in treatment-naive patients in the United States. AIDS Patient Care STDS 2010;24:79-85.
24. Young B, Buchacz K, Moorman A, Wood KC, Brooks JT. Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study. AIDS Patient Care STDS 2009;23:589-592.
25. Scherzer R, Estrella M, Li Y, Deeks SG, Grunfeld C, Shlipak MG. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS Apr 24 2012;26:867-875.
26. Pavie J, Scemla A, Bouldouyre MA, Pillebout E, Verine J, Molina JM. Severe acute renal failure in an HIV-infected patient after only 2 weeks of tenofovir-based antiretroviral therapy. AIDS Patient Care STDS 2011;25:457-460.
27. Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS Feb 1 2012.
28. Chowers MY, Gottesman BS, Leibovici L, Pielmeier U, Andreassen S, Paul M. Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: Systematic review. J Antimicrob Chemother 2009; 64:239-250.
29. Justice AC, Dombrowski E, Conigliaro J, et al. Veterans Aging Cohort Study (VACS): Overview and description. Med Care 2006;44(8 Suppl 2):S13-24. (Pubitemid 44284253)
30. Justice AC, Holmes W, Gifford AL, et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol 2001;54(Suppl 1):S77-90. (Pubitemid 34013693)
31. Ware JE. SF-36 Health Survey Update. www.SF-36.org
32. Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-233. (Pubitemid 126433231)
33. Justice AC, McGinnis KA, Skanderson M, et al. Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers. HIV Med 2010;11:143-151.
34. Beck AT, Guth D, Steer RA, Ball R. Screening for major depression disorders in medical inpatients with the Beck Depression Inventory for Primary Care. Behav Res Ther 1997;35:785-791. (Pubitemid 27336913)
35. Justice AC, FreibergMS, Tracy R, Kuller L, Tate JP, Goetz MB, Fiellin DA, Vanasse GJ, Butt AA, Rodriguez-Barradas MC, Gibert C, Oursler KA, Deeks SD, Bryant K, the VACS Project Team. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis Apr 2012;54:984-994.
36. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care 1988;26:814-823.
37. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105-116. (Pubitemid 27089212)
38. Braithwaite RS, Kozal MJ, Chang CC, et al. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS 2007;21:1579-1589. (Pubitemid 47075479)
39. Silverberg MJ, Gore ME, French AL, et al. Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study. Clin Infect Dis 2004;39:717-724. (Pubitemid 39180446)
40. Harding R, Molloy T. Positive futures? The impact of HIV infection on achieving health, wealth and future planning. AIDS Care 2008;20:565-570.
41. Willard S, Holzemer WL, Wantland DJ, et al. Does asymptomatic mean without symptoms for those living with HIV infection? AIDS Care 2009;21:322-328.
42. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007;146:87-95. (Pubitemid 351640011)
43. Lohse N, Hansen AB, Gerstoft J, Obel N. Improved survival in HIV-infected persons: consequences and perspectives. J Antimicrob Chemother 2007;60:461-463. (Pubitemid 47303950)
44. Lohse N, Gerstoft J, Kronborg G, et al. Comorbidity acquired before HIV diagnosis and mortality in HIV-infected and uninfected persons: A Danish population-based cohort study. J Acquir Immune Defic Syndr Apr 23 2011.
45. Justice AC. HIV and aging: Time for a new paradigm. Curr HIV/AIDS Rep 2010;7:69-76.
46. Hill A, Balkin A. Risk factors for gastrointestinal adverse events in HIV treated and untreated patients. AIDS Rev 2009;11:30-38.
47. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002;346:2039-2046. (Pubitemid 34680595)
48. Spire B, Carrieri P, GarzotMA, L'Henaff M, Obadia Y. Factors associated with efavirenz discontinuation in a large community-based sample of patients. AIDS Care 2004;16:558-564. (Pubitemid 38918087)
49. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: A general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999;15:141-55. (Pubitemid 29093257)
50. Safren SA, Hendriksen ES, Smeaton L, et al. Quality of life among individuals with HIV starting antiretroviral therapy in diverse resource-limited areas of the world. AIDS Behav Apr 16 2011.
51. Institute ofMedicine. AdverseDrug Event Reporting The Roles of Consumers and Health-Care Professionals, Workshop Summary. Washington, D.C.: the Naional Academy Press; 2007.
52. Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: A randomized trial. Ann Intern Med 2011;154:445-456.
53. Justice AC, Chang CH, Rabeneck L, Zackin R. Clinical importance of provider-reported HIV symptoms compared with patient-report. Med Care 2001;39:397-408. (Pubitemid 33603638)
54. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009;360:1815-1826.
55. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: A collaborative analysis of 18 HIV cohort studies. Lancet 2009;373:1352-1363.
56. Zingmond DS, Kilbourne AM, Justice AC, et al. Differences in symptom expression in older HIV-positive patients: The Veterans Aging Cohort 3 Site Study and HIV Cost and Service Utilization Study experience. J Acquir Immune Defic Syndr 2003;33(Suppl 2):S84-92. (Pubitemid 36801606)
57. BonjochA, FiguerasM, Estany C, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 2010;24:2827-2833.